THERAPEUTIC PERSPECTIVES IN MULTIPLE-SCLE ROSIS

Numerous clinical trials have been performed during the last 5 years i n multiple sclerosis patients. Some of the results have been encouragi ng. However, clinical benefit remains limited, Corticosteroids are ind icated during the course of severe relapses but have not proven any lo ng term benefit, Immunosuppressive agents may be of some help during v ery active stages of the disease, Results of interferon beta-1b trial in relapsing multiple sclerosis have shown a moderate decrease in the frequency of relapses. The same effect has recently been reported with interferon beta-1a. In addition, an effect on disability progression have been suggested with the latter interferon, In France, interferon beta-1b is now authorized in the relapsing forms of the disease, Initi al results with copolymer I also suggest an effect on the frequency of relapses, Despite these major therapeutical efforts, further trials, possibly using new therapeutical approaches, are still needed.